Literature DB >> 7555480

Implementation of treatment protocols in the Diabetes Control and Complications Trial.

.   

Abstract

OBJECTIVE: To describe the methods used to implement intensive and conventional therapies in the Diabetes Control and Complications Trial (DCCT) and the metabolic results that occurred with the different treatment regimens. RESEARCH DESIGN AND METHODS: The DCCT was a controlled clinical trial that demonstrated the beneficial effect of intensive therapy on the long-term complications of insulin-dependent diabetes mellitus (IDDM). A total of 1,441 volunteers with IDDM, aged 13-39, from 29 centers in the U.S. and Canada, were randomly assigned to conventional or intensive diabetes therapy. Intensive therapy, which used multiple daily injections (MDI) of insulin ( > or = 3 injections/day) or continuous subcutaneous insulin infusion (CSII), was implemented by a team that included diabetes nurses, dietitians, behavioral experts, and diabetologists. Volunteers in the intensive treatment group could use MDI or CSII, based on patient and clinic preference, and could switch between therapies over the course of the study. The volunteers were followed for a mean of 6.5 years (range 3-9 years).
RESULTS: A detailed analysis of implementation of the two treatments indicates that intensive and conventional treatment subjects adhered to their respective insulin injection regimens > 97% of the time. Adherence to other elements of intensive treatment was similarly high and resulted in median HbA1c values between 6.7 and 7.2, compared with 8.7-9.2 with conventional therapy, over the course of the study. Severe hypoglycemia occurred three times more often in intensively treated subjects. Although subjects on intensive treatment were not randomly assigned to MDI or CSII, we compared those subjects who used either of these methods for > or = 90% of the study time. CSII-treated patients maintained a mean HbA1c of 6.8 vs. 7.0 in MDI-treated subjects during the trial (P < 0.05). The frequency of hypoglycemia with coma and seizure and diabetic ketoacidosis was modestly higher with CSII than with MDI.
CONCLUSIONS: Intensive therapy was implemented successfully in the DCCT. The detailed description herein will serve to facilitate translation of the DCCT results to the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7555480     DOI: 10.2337/diacare.18.3.361

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  43 in total

1.  Continuous subcutaneous insulin infusion in type 1 diabetes.

Authors:  J Pickup; H Keen
Journal:  BMJ       Date:  2001-05-26

Review 2.  Evolving approaches to intensive insulin therapy in type 1 diabetes: multiple daily injections, insulin pumps and new methods of monitoring.

Authors:  Elizabeth Stephens; Matthew Riddle
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 6.514

Review 3.  Does familial clustering of risk factors for long-term diabetic complications leave any place for genes that act independently?

Authors:  Andrew D Paterson; Shelley B Bull
Journal:  J Cardiovasc Transl Res       Date:  2012-06-23       Impact factor: 4.132

Review 4.  Behavior matters.

Authors:  Edwin B Fisher; Marian L Fitzgibbon; Russell E Glasgow; Debra Haire-Joshu; Laura L Hayman; Robert M Kaplan; Marilyn S Nanney; Judith K Ockene
Journal:  Am J Prev Med       Date:  2011-05       Impact factor: 5.043

5.  Accuracy of a new real-time continuous glucose monitoring algorithm.

Authors:  D Barry Keenan; Raymond Cartaya; John J Mastrototaro
Journal:  J Diabetes Sci Technol       Date:  2010-01-01

6.  Diabetes: Insulin pumps in children with T1DM--we told you so.

Authors:  William V Tamborlane; Jennifer L Sherr
Journal:  Nat Rev Endocrinol       Date:  2013-10-01       Impact factor: 43.330

7.  Metabolic environment in substantia nigra reticulata is critical for the expression and control of hypoglycemia-induced seizures.

Authors:  Libor Velísek; Jana Velísková; Ondrej Chudomel; Ka-Lai Poon; Kimberly Robeson; Barbara Marshall; Archana Sharma; Solomon L Moshé
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

8.  Association of diet and lifestyle with glycated haemoglobin in type 1 diabetes participants in the EURODIAB prospective complications study.

Authors:  S N Balk; D A J M Schoenaker; G D Mishra; M Toeller; N Chaturvedi; J H Fuller; S S Soedamah-Muthu
Journal:  Eur J Clin Nutr       Date:  2015-07-15       Impact factor: 4.016

Review 9.  Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.

Authors:  Ajay V Maker; Raashid Sheikh; Vinita Bhagia
Journal:  Langenbecks Arch Surg       Date:  2017-07-21       Impact factor: 3.445

10.  Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Authors:  Denis Raccah; Véronique Sulmont; Yves Reznik; Bruno Guerci; Eric Renard; Hélène Hanaire; Nathalie Jeandidier; Marc Nicolino
Journal:  Diabetes Care       Date:  2009-09-18       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.